Please login to the form below

Not currently logged in
Email:
Password:

QMF149

This page shows the latest QMF149 news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals full phase 3 results for Enerzair Breezhaler

Novartis reveals full phase 3 results for Enerzair Breezhaler

function compared to treatment with once-daily QMF149  (indacaterol acetate and mometasone furoate). ... The overall occurrence of adverse events and serious adverse events for both Enerzair Breezhaler and QMF149 in the study were generally low and

Latest news

  • Novartis strengthens case for its combination asthma drug Novartis strengthens case for its combination asthma drug

    The  asthma combination regimen, QMF149, is a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate. ... QMF149 also met the secondary endpoint of the study, demonstrating a statistically significant improvement in asthma

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...